Latest Breaking News On - Luminance dependent navigation assessment - Page 1 : comparemela.com

Ocugen Provides Business Update with First Quarter 2024 Financial Results

Ocugen Provides Business Update with First Quarter 2024 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Shankar musunuriExchange commissionHead of communicationsOcugen incProvides business updateFirst quarterLicense applicationMarket authorization applicationChief executive officerLuminance dependent navigation assessmentData safetyMonitoring boardGene therapiesMarketing authorization applicationCell therapiesGood manufacturing practice

Ocugen, Inc Announces U S FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

MALVERN, Pa., April 08, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the.

United statesTarun upadhyayShankar musunuriOcugen incDrug administrationExchange commissionCompany investigational new drugHead of communicationsInvestigational new drugMulti luminance mobility testingLuminance dependent navigation assessmentLux levelsChief scientific officerHuma qamarChief medical officerPrivate securities litigation reform act